SCHEMBL6239489

SCHEMBL6239489

c1ccc(CNc2ccnc(Nc3ccc4cn[nH]c4c3)n2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.57
IGF1R P08069 4/20 0.57
CLK2 P49760 4/20 0.57
DYRK1A Q13627 4/20 0.57
CLK4 Q9HAZ1 4/20 0.57
DAPK3 O43293 3/20 0.57
PRKD3 O94806 3/20 0.57
MAP4K4 O95819 3/20 0.57
PAK4 O96013 3/20 0.57
PIM1 P11309 3/20 0.57
PRKACA P17612 3/20 0.57
CDK2 P24941 3/20 0.57
FLT3 P36888 3/20 0.57
SYK P43405 3/20 0.57
CSNK1A1 P48729 3/20 0.57
CDK9 P50750 3/20 0.57
JAK3 P52333 3/20 0.57
CDK5 Q00535 3/20 0.57
MAP4K2 Q12851 3/20 0.57
STK3 Q13188 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6259622 0.92 PTK2 (0.67) KDRIGF1RCLK2DYRK1ACLK4
SCHEMBL6262359 0.90 KDR (0.56) KDRIGF1RCLK2DYRK1ACLK4
SCHEMBL6260019 0.86 PTK2 (0.52) KDRIGF1RCLK2DYRK1ACLK4
SCHEMBL15426063 0.84 INSR (0.54) IGF1RCLK2CLK4PKN2STK17A
SCHEMBL6258964 0.84 SYK (0.47) KDRIGF1RDYRK1ACLK4SYK
SCHEMBL6211361 0.82 PTK2 (0.64) KDRIGF1RCLK2DYRK1ACLK4
SCHEMBL6209186 0.82 PTK2 (0.64) KDRIGF1RCLK2DYRK1ACLK4
SCHEMBL6236364 0.81 KDR (0.58) KDRIGF1RCLK2DYRK1ACLK4
SCHEMBL6216051 0.81 AURKA (0.61) KDRIGF1RSYKPLK4FGFR1
SCHEMBL14292689 0.81 KDR (0.60) KDRIGF1RCLK2DYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 KDR 741/4885IGF1R 93/4885CLK2 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.